The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy.
 
Elizabeth Iannotti Buchbinder
Employment - Alexion Pharmaceuticals (I)
Consulting or Advisory Role - Apexigen; Bristol-Myers Squibb; Novartis; Shionogi
Research Funding - Bristol-Myers Squibb; Checkmate Pharmaceuticals; Genentech/Roche; Lilly; Novartis
 
Kathleen L. Pfaff
No Relationships to Disclose
 
Michael P. Manos
No Relationships to Disclose
 
Olivia Ouyang
No Relationships to Disclose
 
Patrick Alexander Ott
Consulting or Advisory Role - Array BioPharma; Bristol-Myers Squibb; Celldex; CytomX Therapeutics; Genentech; Merck; Novartis; Pfizer
Research Funding - ARMO BioSciences (Inst); AstraZeneca/MedImmune (Inst); Bristol-Myers Squibb (Inst); Celldex (Inst); CytomX Therapeutics (Inst); Genentech (Inst); GlaxoSmithKline (Inst); Merck (Inst); Neon Therapeutics (Inst); Pfizer (Inst)
Expert Testimony - Boehringer Ingelheim
 
Scott J. Rodig
Leadership - Immunitas
Stock and Other Ownership Interests - Immunitas
Honoraria - Bristol-Myers Squibb; Perkin Elmer
Consulting or Advisory Role - Bristol-Myers Squibb
Research Funding - Affimed Therapeutics; Bristol-Myers Squibb; Kite, a Gilead company; Merck
Patents, Royalties, Other Intellectual Property - Patent pending for use of Anti-galectin1 antibodies for diagnostic use.
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Roche
 
F. Stephen Hodi
Employment - Dana-Farber Cancer Institute
Stock and Other Ownership Interests - Apricity Health; Torque
Consulting or Advisory Role - 7 Hills Pharma; Aduro Biotech; Amgen; Bayer; Boston Pharmaceuticals; Bristol-Myers Squibb; Checkpoint THerapeutics; Compass Therapeutics; Eisai; EMD Serono; Genentech/Roche; Merck Sharp & Dohme; Novartis; Partners Therapeutics; Pfizer; Pionyr; Rheos Medicines; Sanofi; Surface Oncology; Takeda; Torque; Verastem
Research Funding - bristol-myers squibb (Inst); Genentech/Roche (Inst); Merck Sharp & Dohme (Inst); novartis (Inst)
Patents, Royalties, Other Intellectual Property - Angiopoietin-2 Biomarkers Predictive of Anti-immune checkpoint response (Inst); Compositions and Methods for Identification, Assessment, Prevention, and Treatment of Melanoma using PD-L1 Isoforms; Methods of Using Pembrolizumab and Trebananib (Inst); patent pending as per institutional policy; patent pending royalties received on MICA related disorders application to institution per institutional IP policy
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Novartis
Other Relationship - Bristol-Myers Squibb; Genentech/Roche